Showing 1 - 10 of 58 Cancers and Other Neoplasms

Status: Enrolling

Investigator: Warren Ellsworth

Study Coordinator: Adrienne New

Phone: 713.441.3250

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

Breast implants are the most common way of rebuilding the shape of the breasts after breast cancer surgery. However, current breast implants cannot completely match individual differences in breast shape. It is also often difficult to match the ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

The purpose of this study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy. This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicente ... Read more >

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally adv ... Read more >

Status: Enrolling

Investigator: Aldona Spiegel

Study Coordinator: Adrienne New

Phone: 713.441.3250

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

Status: Enrolling

Investigator: Jasleen Randhawa

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab. ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain and also to determine the overall radiographic response rate in the CNS. Palbociclib is an anti ... Read more >

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Minh Truong

Phone: 346.238.6403

This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving surgery. Tumor tissue collected from biopsy before surgery ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutation ... Read more >

Status: Enrolling

Investigator: Raj Satkunasivam

Study Coordinator: Cinthya Yesenia Obando Perez

Phone: 346.238.6123

This study is for subjects that have high grade bladder cancer that has not entered the muscle. In the U.S., people who are not in a study are usually treated with BCG LIVE (TICE® BCG) (an abbreviation for Bacillus Calmette–Guérin), which is a b ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with ... Read more >

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is a pilot study is evaluating the effect of hydroxytyrosol, a component of Olive oil, on mammographic density in women at high risk of breast through assessing whether mammographic density is reduced in women at high risk of breast cancer ... Read more >

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet know ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

Reparixin oral tablets are being tested as a CSC targeting agent in patients with metastatic non- human epidermal growth factor receptor (HER2)-amplified BC. An open label Phase 1b clinical study (REP0111) is ongoing (enrollment completed) in fi ... Read more >

Status: Enrolling

Investigator: David Baskin

Study Coordinator: Larisse Yewah Gwei

Phone: 713.441.3834

This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) follow ... Read more >

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Minh Truong

Phone: 346.238.6403

This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. ... Read more >

Status: Enrolling

Investigator: Jorge Darcourt

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

This is a study that will test how an experimental drug (enfortumab vedotin) affects patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra that has spr ... Read more >

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Denesha Potts

Phone: 713.441.6011

The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first-line treatment) as measured by Progression Free Survival (PFS). This study will also ev ... Read more >

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Denesha Potts

Phone: 713.441.6011

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement. < ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Meena Medepalli

Phone: 713.441.4203

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment ... Read more >

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Minh Truong

Phone: 346.238.6403

A single arm pilot study of 20 patients will be used to determine the feasibility of EA as a treatment for cancer survivors who have been treated with curative intent, but who have persistent CIPN for ≥3 months after the cancer treatment is comp ... Read more >

Status: Open Not Enrolling

Investigator: Brian Miles

Study Coordinator: Vivian MacDonnell

Phone: 714.441.8113

This is a phase 1/2a clinical trial in subjects who are diagnosed with prostate cancer to evaluate the effectiveness of Ad5-SGE-REIC/Dkk-3 in the treatment of localized prostate cancer. Subjects enrolled will be diagnosed with localized prostat ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Meena Medepalli

Phone: 713.441.4203

This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in diffe ... Read more >

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

Open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with wild-typ ... Read more >

Status: Open Not Enrolling

Investigator: Jasleen Randhawa

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine ... Read more >

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

This is a study to determine the maximum tolerated dose (MTD) for CDX-1140, either alone or in combination with CDX-301, and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined. ... Read more >

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Pej Hemati

Phone: 713.441.3926

This is a Phase Ib/II study assessing the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), recommended Phase 2 dose (RP2D), and efficacy of L-NMMA when combined with docetaxel in refractory locally advanced or metastatic triple neg ... Read more >

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Denesha Potts

Phone: 713.441.6011

This randomized phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread to other places in ... Read more >

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Jose Cruz

Phone: 713.441.4457

The reason for this trial is to compare DS-8201a to other treatments being used for HER2-low breast cancer that has spread to other parts of the body. DS-8201a is a new medicine for breast cancer that has not been approved yet by the Food and ... Read more >

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Jose Cruz

Phone: 713.441.4457

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane. ... Read more >

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Toniva Boone

Phone: 713.441.0686

Primary Objective: • To compare the efficacy of DS-8201a to investigator’s choice by means of progression-free survival (PFS). Secondary Objectives: • To further investigate the efficacy of DS-8201a compared to investigator’s choice on: − ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3 ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Denesha Potts

Phone: 713.441.6011

This is a Phase II trial to determine the efficacy and safety of in situ gene therapy and stereotactic body radiation therapy (SBRT) used as a window of opportunity treatment before nivolumab in patients with metastatic squamous and non-squamous ... Read more >

Status: Enrolling

Investigator: Aparna Kamat

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

This randomized phase III trial is studying chemotherapy and pelvic radiation therapy to see how well they work when given with or without additional chemotherapy in treating patients with high-risk early-stage cervical cancer after radical hyst ... Read more >

Status: Open Not Enrolling

Investigator: Aparna Kamat

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants wi ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer. ... Read more >

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Denesha Potts

Phone: 713.441.6011

PURPOSE: This randomized phase II/III trial studies how well chemotherapy alone compared to chemotherapy plus radiation therapy works in treating patients with rectal cancer undergoing surgery. ... Read more >

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Helga Jones

Phone: 713.363.9388

Purpose The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site pr ... Read more >

Status: Enrolling

Investigator: David Baskin

Study Coordinator: Larisse Yewah Gwei

Phone: 713.441.3834

This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects u ... Read more >

Status: Open Not Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). ... Read more >

Status: Enrolling

Investigator: Jorge Darcourt

Study Coordinator: Lacey Burey

Phone: 713.441.1159

The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This is a phase Ib/II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC). Study population will consist of patients with CCR5-positive, locally advanced or metastati ... Read more >

Status: Enrolling

Investigator: Jorge Darcourt

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy. At least 140 patients are anticipated to be enrolle ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast cancer who have failed anthracycline based therap ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Denesha Potts

Phone: 713.441.6011

This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with metastatic triple neg ... Read more >

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Larisse Yewah Gwei

Phone: 713.441.3834

NCT03603405 This is a prospective, phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy for anaplastic astrocytoma (AA) or glioblastoma mul ... Read more >

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Larisse Yewah Gwei

Phone: 713.441.3834

NCT03596086 This is a prospective phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy in recurrent anaplastic astrocytoma or glioblastoma ... Read more >

Status: Open Not Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is an international, multi-center, open-label, randomized, Phase III study in patients with metastatic TNBC refractory or relapsing after at least 2 prior chemotherapies (including a taxane) for their metastatic disease. Patients meeting el ... Read more >

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Jose Cruz

Phone: 713.441.4457

The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreat ... Read more >

Status: Open Not Enrolling

Investigator: Kirk Heyne

Study Coordinator: Denesha Potts

Phone: 713.441.6011

This randomized phase III trial studies sorafenib tosylate and stereotactic body radiation therapy to see how well they work compared to sorafenib tosylate alone in treating patients with liver cancer. Sorafenib tosylate may stop the growth of t ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Meena Medepalli

Phone: 713.441.4203

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop t ... Read more >

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Minh Truong

Phone: 346.238.6403

This study is investigating whether breast cancer patients who experience vaginal dryness while on anti-estrogen treatment could benefit from either vaginal estrogen or from a vaginal moisturizer called Replens. ... Read more >

Status: Open Not Enrolling

Investigator: Rafik Ghobrial

Study Coordinator: Darrel Cleere

Phone: 713.441.6232

The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation. Liver transplantation is a treatment option f ... Read more >

Status: Enrolling

Investigator: Kirk Heyne

Study Coordinator: Pej Hemati

Phone: 713.441.3926

This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced uro ... Read more >

Status: Enrolling

Investigator: Jasleen Randhawa

Study Coordinator: Denesha Potts

Phone: 713.441.6011

The purpose of this pivotal study is to compare the efficacy of ABL001 with that of bosutinib in the treatment of patients with CML-CP having previously been treated with a minimum of two prior ATP-binding site TKIs. ... Read more >

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and ... Read more >

Status: Enrolling

Investigator: Mark Sultenfuss

Study Coordinator: Sergio Ibarra Cortez

Phone: 956.543.5198

This research registry studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting Selective Internal Radiation-Spheres (SIR-spheres ... Read more >

Live Chat Available